- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03109834
Effect of Weight Management Programs on Cardiometabolic Risk Profile in Overweight Women (FM-01)
Choice of Foods, Weight Loss and Metabolic Changes in Overweight Women Willing to Lose Weight With Dietary/Nutritional Therapy Intervention
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Abdominal obesity, atherogenic dyslipidemia and hypertension are essential risk factors for cardiovascular diseases. Several studies showed favorable effects of weight loss in overweight subjects on cardiometabolic risk profile.
The study was divided into a 3-month weight loss phase (phase 1), a subsequent 3-month phase of weight stabilization (phase 2) and a 6-month phase of weight loss maintenance (phase 3).
For a total of 6 months subjects were randomly assigned to the meal replacement (MR) or control (C) group at baseline I.
During weight loss phase both dietary intervention groups followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d. The MR-WL group (MR group during weight loss phase) was advised to replace two of three meals every day with meal replacements. The C-WL group (C group during weight loss phase) was advised to follow a conventional energy-restricted modified diet with 15-20% of energy intake in the form of protein, 50-55% of energy intake in the form of carbohydrates and 30% of energy intake in the form of fat. All participants attended ten group training sessions for nutrition education.
During weight stabilization phase all women of MR-S and C-S group (MR and C group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. However, the MR-S and C-S group were instructed to continue the implemented nutrition advice of weight loss phase.
At the beginning of weight loss maintenance phase (baseline II) women were randomly assigned to the verum (specific micronutrient composition with omega-3 fatty acids) group or placebo group. Both groups were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods.
All women participated in an exercise program (fitness walking) on 1-2 days per week during all three phases of the study for a total of 12 months.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI: between 27.0 and 34.9 kg/m²
- One of the following blood lipids: total cholesterol ≥ 200 mg/dL, LDL-cholesterol ≥ 175 mg/dL, HDL-cholesterol ≤ 50 mg/dL, TG 150-400 mg/dL
- women, 18-60 years
Specific Exclusion Criteria:
- lactose or protein intolerance
- hypo- or hyperthyroidism
- pharmacological treatment of diabetes
- intake of vitamins or mineral supplements
- anticoagulants
- cardiac pacemaker
- contraindications to exercise
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Meal replacement (MR) group
Energy-restricted modified diet with MR for weight control dietary supplement: MR shakes, soups or bars. Duration: 3-month weight loss phase (phase 1) During weight stabilization phase (phase 2) MR counted to food choice option. |
MR-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d and was advised to replace two meals, i.e. breakfast and dinner, every day with two MR shakes, soups or bars and to prepare their own lunch during 3-month weight loss phase (phase 1). During 3-month weight stabilization phase (phase 2) MR-S group (MR group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The MR-S group was instructed to continue the implemented nutrition advice of weight loss phase. Duration: 6 months (phase 1 and phase 2: baseline I - 6.month) |
OTHER: Control (C) group
Energy-restricted modified diet without MR for weight control. Duration: 3-month weight loss phase (phase 1) During 3-month weight stabilization phase (phase 2) MR counted to food choice option. |
During 3-month weight loss phase (phase 1) C-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d without MR for weight control. During 3-month weight stabilization (phase 2) phase C-S group (C group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The C-S group was instructed to continue the implemented nutrition advice of weight loss phase. Duration: 6 months (phase 1 and phase 2: baseline I - 6.month) |
ACTIVE_COMPARATOR: Verum group
Specific micronutrient composition with omega-3 fatty acids (capsules) Duration: 6-month weight maintenance phase (phase 3) |
Verum: Specific micronutrient composition with omega-3 fatty acids (capsules) Verum group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 verum-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase (phase 3). Duration: 6 months (6.month / baseline II - 12.month) |
PLACEBO_COMPARATOR: Placebo group
Placebo capsules Duration: 6-month weight maintenance phase (phase 3) |
Placebo group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 placebo-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase. Placebo contains no micronutrients and omega-3 fatty acids. Duration: 6 months (6.month / baseline II - 12.month) |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight loss (phase 1)
Time Frame: 3-month dietary intervention (from baseline I to 3rd month)
|
Intervention changes in body weight
|
3-month dietary intervention (from baseline I to 3rd month)
|
Total antioxidant capacity (phase 3)
Time Frame: 6-month dietary intervention (from baseline II to 12th month)
|
Intervention changes in total antioxidant capacity
|
6-month dietary intervention (from baseline II to 12th month)
|
Fasting plasma cortisol concentration (phase 3)
Time Frame: 6-month dietary intervention (from baseline II to 12th month)
|
Intervention changes in fasting plasma cortisol concentration
|
6-month dietary intervention (from baseline II to 12th month)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative body fat (phase 1)
Time Frame: 3-month dietary intervention (from baseline I to 3rd month)
|
Intervention changes in relative body fat
|
3-month dietary intervention (from baseline I to 3rd month)
|
Relative body weight (phase 1)
Time Frame: 3-month dietary intervention (from baseline I to 3rd month)
|
Intervention changes in relative body weight
|
3-month dietary intervention (from baseline I to 3rd month)
|
Responder (weight loss > 5%) (phase 1)
Time Frame: 3-month dietary intervention (from baseline I to 3rd month)
|
Responder rate after 12 weeks
|
3-month dietary intervention (from baseline I to 3rd month)
|
Waist circumference (phase 1)
Time Frame: 3-month dietary intervention (from baseline I to 3rd month)
|
Intervention changes in waist circumference
|
3-month dietary intervention (from baseline I to 3rd month)
|
Total antioxidant capacity (phase 1)
Time Frame: 3-month dietary intervention (from baseline I to 3rd month)
|
Intervention changes in total antioxidant capacity
|
3-month dietary intervention (from baseline I to 3rd month)
|
Fasting plasma cortisol concentration (phase 1)
Time Frame: 3-month dietary intervention (from baseline I to 3rd month)
|
Intervention changes in fasting plasma cortisol concentration
|
3-month dietary intervention (from baseline I to 3rd month)
|
Relative body fat (phase 3)
Time Frame: 6-month dietary intervention (from baseline II to 12th month)
|
Intervention changes in relative body fat
|
6-month dietary intervention (from baseline II to 12th month)
|
Relative body weight (phase 3)
Time Frame: 6-month dietary intervention (from baseline II to 12th month)
|
Intervention changes in relative body weight
|
6-month dietary intervention (from baseline II to 12th month)
|
Responder (weight loss > 5%)
Time Frame: 12 months (from baseline I to 12th month)
|
Responder rate after 12 months
|
12 months (from baseline I to 12th month)
|
Waist circumference (phase 3)
Time Frame: 6-month dietary intervention (from baseline II to 12th month)
|
Intervention changes in waist circumference
|
6-month dietary intervention (from baseline II to 12th month)
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BFD-01/FM-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight and Obesity
-
University Hospital, LilleNational Research Agency, France; European Union; University of Lille Nord de... and other collaboratorsNot yet recruitingOverweight and Obesity | Overweight, Childhood | Overweight, Infant
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Institut Investigacio Sanitaria Pere VirgiliCompletedObesity, Childhood | Overweight and Obesity | Overweight, ChildhoodSpain
-
Memorial Sloan Kettering Cancer CenterRecruitingObesity | Overweight | Overweight and Obesity | Obese | Overweight or ObesityUnited States
-
Holbaek SygehusUniversity of Copenhagen; University of Florida; University of Minnesota; Hebrew... and other collaboratorsRecruitingChildhood Overweight and ObesityDenmark
-
Universidade do Extremo Sul Catarinense - Unidade...RecruitingObesity | Overweight and Obesity | Obesity; Endocrine | Overweight, Obesity and Other HyperalimentationBrazil
-
Mexican National Institute of Public HealthUNICEFCompleted
-
Universidade do PortoFundação para a Ciência e a Tecnologia; Administração Regional de Saúde do... and other collaboratorsCompletedOverweight and ObesityPortugal
-
University of British ColumbiaTerminatedOverweight and ObesityCanada
-
National Taiwan University HospitalCompleted
Clinical Trials on Meal replacement (MR)
-
Children's Hospital SrebrnjakBelupo; Podravka d.d.Recruiting
-
Children's Hospital SrebrnjakBelupo; Podravka d.d.RecruitingBody Weight | Overweight and ObesityCroatia
-
Khoo Teck Puat HospitalCompletedThe Effect of Intermittent Energy Restriction Using Meal Replacements in Overweight Chinese SubjectsObesity | FastingSingapore
-
University of North Carolina, Chapel HillCompletedOverweight | Obese | Body Composition, Beneficial | Satiety | Basal Metabolic RateUnited States
-
Teatis, IncCitruslabsNot yet recruitingDiabetes Mellitus, Type 2United States
-
University of MinnesotaCompletedPediatric Obesity | Obesity, SevereUnited States
-
Chung Shan Medical UniversityCompletedObesity | Diet Modification | Nutrient; ExcessTaiwan
-
Massachusetts General HospitalRecruitingObesity | Overweight | PreDiabetes | Diabetes Type 2United States
-
Ann & Robert H Lurie Children's Hospital of ChicagoRecruitingChildhood ObesityUnited States
-
Iowa State UniversityNational Institute on Aging (NIA)CompletedMild Cognitive ImpairmentUnited States